E
Syndax Pharmaceuticals, Inc. SNDX
$10.78 $0.0750.70% NASDAQ
Recommendation
Prev Close
$10.70
Volume
197,512
Avg Vol (90D)
2,224,923
Market Cap
$920.71M
Dividend & Yield
--
52-Week Range
$9.66 - $25.07
P/E (TTM)
--
EPS (TTM)
-$3.87
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Bayesian Capital Management LP Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
5/10/2025 - MarketBeat
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
5/9/2025 - Zacks Investment Research
Syndax Pharmaceuticals (SNDX, $11.01) RSI Indicator left the oversold zone on May 08, 2025
5/9/2025 - Tickeron - Stocks
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $17.00
5/9/2025 - Ticker Report
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $17.00
5/8/2025 - MarketBeat
Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at Guggenheim
5/8/2025 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS
5/8/2025 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by DAFNA Capital Management LLC
5/8/2025 - Ticker Report
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Position Increased by Crestline Management LP
5/8/2025 - MarketBeat
Syndax Announces Participation in May Investor Conferences
5/8/2025 - Globe Newswire
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results
5/8/2025 - Simply Wall St
Syndax Pharmaceuticals (SNDX, $9.99) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 7, 2025
5/8/2025 - Tickeron - Technical Analysis
Syndax Pharmaceuticals (SNDX, $9.99) RSI Indicator left the oversold zone on May 07, 2025
5/8/2025 - Tickeron - Technical Analysis
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
5/7/2025 - Globe Newswire
Syndax Pharmaceuticals (SNDX, $10.64) price exceeded its 50-day Moving Average on May 06, 2025
5/7/2025 - Tickeron - Stocks
Syndax Pharmaceuticals (SNDX, $10.64) entered Downtrend as Momentum indicator drops below 0 level on May 06, 2025
5/7/2025 - Tickeron - Technical Analysis
Syndax Pharmaceuticals (SNDX, $10.64) Stochastic Oscillator left the overbought zone on May 06, 2025
5/7/2025 - Tickeron - Technical Analysis
SNDX: Scotiabank Raises Price Target on Syndax Pharmaceuticals SNDX Stock News
5/6/2025 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results, Beats Estimates By $0.26 EPS
5/6/2025 - Ticker Report
Video: Tuesday's ETF Movers: TAN, XBI
5/6/2025 - Market News Video
Video: Tuesday Sector Laggards: Biotechnology, Drugs
5/6/2025 - Market News Video
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenheim SNDX Stock News
5/6/2025 - GuruFocus
Avidity Partners Management LP Trims Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
5/6/2025 - MarketBeat
Algert Global LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
5/6/2025 - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
5/6/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$43.72M
EBITDA (TTM)
-$343.66M
EBIT (TTM)
-$343.67M
Net Income (TTM)
-$331.20M
Balance Sheet
Total Assets (Q)
$640.71M
Total Debt (Q)
$345.63M
Total Liabilities (Q)
$425.65M
Book Value Per Share (Q)
$2.50
Cash Flow
Cash from Operations (TTM)
-$286.52M
Cash from Investing (TTM)
-$26.23M
Cash from Financing (TTM)
$352.13M
Net Change in Cash (TTM)
$39.38M
Filings
Filing Date
Monday, May 5, 2025
Period Date
Monday, March 31, 2025
Next Filing
Beginning of August (est)
Price History
Loading...
Beta
1.40
7-Day Total Return
-22.07%
30-Day Total Return
-18.29%
60-Day Total Return
-28.58%
90-Day Total Return
-13.98%
Year to Date Total Return
-23.51%
1-Year Total Return
-50.48%
2-Year Total Return
-47.13%
3-Year Total Return
-28.86%
5-Year Total Return
-41.69%
52-week Low
Apr 09, 2025 - $9.66
52-week High
Jul 16, 2024 - $25.07
Valuation
Market Cap
$920.71M - Small Cap
Enterprise Value
$750.02M
Price/Sales (TTM)
21.09
Price/Book (Q)
4.28
Dividends and Shares
Shares Outstanding
86.17M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
syndax.com
Phone Number
781 419 1400
Address
730 Third Avenue
New York, NY 10017
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin... more
NASDAQ 05/12/2025 10:27AM Eastern Quotes delayed